Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orexin Receptor Antagonism, a New Sleep-Promoting Paradigm: An Ascending Single-Dose Study With Almorexant
Petra Hoever, SL de Haas, Julia Winkler, et al.
Clinical Pharmacology & Therapeutics (2010) Vol. 87, Iss. 5, pp. 593-600
Closed Access | Times Cited: 101

Showing 26-50 of 101 citing articles:

Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist
Paolo Bettica, Gianluca Nucci, Caroline K. Pyke, et al.
Journal of Psychopharmacology (2011) Vol. 26, Iss. 8, pp. 1058-1070
Closed Access | Times Cited: 59
Neuropeptides Controlling Energy Balance: Orexins and Neuromedins
Joshua P. Nixon, Catherine M. Kotz, Colleen M. Novak, et al.
Handbook of experimental pharmacology (2011), pp. 77-109
Open Access | Times Cited: 52
The dual orexin receptor antagonist almorexant, alone and in combination with morphine, cocaine and amphetamine, on conditioned place preference and locomotor sensitization in the rat
Michel A. Steiner, Hugues Lecourt, François Jenck
The International Journal of Neuropsychopharmacology (2012) Vol. 16, Iss. 2, pp. 417-432
Open Access | Times Cited: 50
Effects of a single, oral 60 mg caffeine dose on attention in healthy adult subjects
Micha M.M. Wilhelmus, Justin L. Hay, Rob Zuiker, et al.
Journal of Psychopharmacology (2016) Vol. 31, Iss. 2, pp. 222-232
Closed Access | Times Cited: 41
The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders
Christoph Boss, John Gatfield, Christine Brotschi, et al.
ChemMedChem (2020) Vol. 15, Iss. 23, pp. 2286-2305
Closed Access | Times Cited: 37
Differential Effects of the Dual Orexin Receptor Antagonist Almorexant and the GABAA-α1 Receptor Modulator Zolpidem, Alone or Combined with Ethanol, on Motor Performance in the Rat
Michel A. Steiner, Hugues Lecourt, Daniel S. Strasser, et al.
Neuropsychopharmacology (2010) Vol. 36, Iss. 4, pp. 848-856
Open Access | Times Cited: 46
Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference
Jed Black, Giora Pillar, Jan Hedner, et al.
Sleep Medicine (2017) Vol. 36, pp. 86-94
Closed Access | Times Cited: 39
Neurobiology and sleep disorders in cluster headache
Mads Barloese
The Journal of Headache and Pain (2015) Vol. 16, Iss. 1
Open Access | Times Cited: 38
Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate
Michael A. Letavic, Pascal Bonaventure, Nicholas I. Carruthers, et al.
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 14, pp. 5620-5636
Closed Access | Times Cited: 38
Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs
Anil Kumar, Priyanka Chanana, Supriti Choudhary
Pharmacological Reports (2015) Vol. 68, Iss. 2, pp. 231-242
Closed Access | Times Cited: 35
Orexin OX2 Receptor Antagonists as Sleep Aids
Laura H. Jacobson, Sui Chen, Sanjida Mir, et al.
Current topics in behavioral neurosciences (2016), pp. 105-136
Open Access | Times Cited: 35
Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice
Carrie E. Mahoney, Takatoshi Mochizuki, Thomas E. Scammell
SLEEP (2019) Vol. 43, Iss. 6
Open Access | Times Cited: 30
Therapeutic implications of the choroid plexus–cerebrospinal fluid interface in neuropsychiatric disorders
Delphine Demeestere, Claude Libert, Roosmarijn E. Vandenbroucke
Brain Behavior and Immunity (2015) Vol. 50, pp. 1-13
Closed Access | Times Cited: 33
Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration
Clemens Muehlan, Margaux Boehler, Sander Brooks, et al.
Journal of Psychopharmacology (2019) Vol. 34, Iss. 3, pp. 326-335
Closed Access | Times Cited: 29
Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers
Francis M. Dijkstra, Patricio O’Donnell, Erica S. Klaassen, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 14
Sleep and its disorders in translational medicine
Louise M. Paterson, David Nutt, Sue Wilson
Journal of Psychopharmacology (2011) Vol. 25, Iss. 9, pp. 1226-1234
Closed Access | Times Cited: 32
Current Phase II investigational therapies for insomnia
Nava Zisapel
Expert Opinion on Investigational Drugs (2014) Vol. 24, Iss. 3, pp. 401-411
Closed Access | Times Cited: 28
Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Dose Almorexant, an Orexin Receptor Antagonist, in Healthy Elderly Subjects
Petra Hoever, Justin L. Hay, Mandana Rad, et al.
Journal of Clinical Psychopharmacology (2013) Vol. 33, Iss. 3, pp. 363-370
Closed Access | Times Cited: 27
Dual Orexin Receptor Antagonist, Almorexant, in Elderly Patients With Primary Insomnia: A Randomized, Controlled Study
Thomas Roth, Jed Black, Raymond Cluydts, et al.
SLEEP (2016) Vol. 40, Iss. 2
Open Access | Times Cited: 25
Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass Spectrometry
Clemens Muehlan, Hartmut Fischer, Dieter Zimmer, et al.
Current Drug Metabolism (2019) Vol. 20, Iss. 4, pp. 254-265
Closed Access | Times Cited: 23
First‐in‐human study with ACT‐539313, a novel selective orexin‐1 receptor antagonist
Priska Kaufmann, Marion Anliker‐Ort, Georg Golor, et al.
British Journal of Clinical Pharmacology (2020) Vol. 86, Iss. 7, pp. 1377-1386
Open Access | Times Cited: 23
Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial
Thomas C. Neylan, Anne Richards, Thomas J. Metzler, et al.
SLEEP (2020) Vol. 43, Iss. 10
Open Access | Times Cited: 22
Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects
Matthias Hoch, Petra Hoever, Federica Alessi, et al.
European Journal of Clinical Pharmacology (2012) Vol. 69, Iss. 3, pp. 523-532
Closed Access | Times Cited: 27
Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon
Sonia Thomas, Viral Goradia
Drugs in Context (2013), pp. 1-10
Open Access | Times Cited: 26
Entry‐into‐humans study with ACT‐462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant
Matthias Hoch, Helene C. van Gorsel, Joop van Gerven, et al.
The Journal of Clinical Pharmacology (2014) Vol. 54, Iss. 9, pp. 979-986
Closed Access | Times Cited: 23

Scroll to top